Michael J. Rauh

Medicine · Health Sciences

31h-index4.5kcitations184works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(66), Myeloproliferative Neoplasms: Diagnosis and Treatment(43), Immune cells in cancer(25), Epigenetics and DNA Methylation(24), Hemoglobinopathies and Related Disorders(21)

Publications183 total

Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Data from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
2026Open Access
Uterine scar tissues homing endometrial-like cells present aberrant structures and altered immune milieu
Zeitschrift für Geburtshilfe und Neonatologie·2025
Physische und psychische Verträglichkeit der Einnahme eines Gestagen-Monopräparats bei Frauen mit Kinderwunsch
Zeitschrift für Geburtshilfe und Neonatologie·2025
Extracellular Vesicles Define Discrete Nano‐Based Niches Within the Human Haematopoietic System
Journal of Extracellular Vesicles·2025Open Access
Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Cancer Research·2025· 1 cited
Asxl1 mutant cells suppress Dnmt3a mutant clonal expansion.
Blood·2025
page 1 of 10Next →

Frequent Co-authors

Caitlyn Vlasschaert(14), Brooke Snetsinger(9), Alexander G. Bick(9), Gerald Krystal(8), Pradeep Natarajan(8), Matthew B. Lanktree(8), Laura M. Sly(7), Janet Kalesnikoff(6), Elina K. Cook(6), Rena Buckstein(5), Bryan Kestenbaum(5), Cassianne Robinson‐Cohen(5), Vivian Lam(4), Alyssa Cull(4), Christina K. Ferrone(4), Amy J. M. McNaughton(4), Raymond C. Harris(4), Marco M. Buttigieg(4), Ross L. Levine(3), J. Brett Heimlich(3)